NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03246529,"A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)",https://clinicaltrials.gov/study/NCT03246529,GENESIS,ACTIVE_NOT_RECRUITING,A total of 122 subjects were randomized into the study and investigated in the double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo.,YES,Multiple Myeloma,DRUG: BL-8040 1.25 mg/kg + G-CSF|DRUG: Placebo +G-CSF,"Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions, Percentage of subjects mobilizing ≥6 × 10\^6 CD34+ cells/kg with up to 2 apheresis sessions in preparation for autologous hematopoetic cell transplantation (auto-HCT) after treatment with G-CSF + single administration of BL-8040/placebo.

Based on central laboratory data., From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6","Percentage of Subjects Mobilizing ≥2 × 10^6 CD34+ Cells/kg in 1 Apheresis Session, Percentage of subjects mobilizing ≥2 × 10\^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo., From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5|Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg in 1 Apheresis Session, Percentage of subjects mobilizing ≥6 × 10\^6 CD34+ cells/kg in 1 apheresis session after treatment with G-CSF + single administration of BL-8040/ placebo., From first day of study treatment (G-CSF) until day of first apheresis which was planned to occur on Day 5|Time to Neutrophil Engraftment, After Auto-HCT, Time to neutrophil engraftment after auto-HCT, where engraftment was defined as absolute neutrophil count (ANC) ≥0.5 × 10\^9/L for 3 days or ≥1.0 × 10\^9/L for 1 day following the conditioning regimen associated nadir., End of engraftment period, which was defined as 29 days post transplantation|Time to Platelet Engraftment, After Auto-HCT, Time to platelet engraftment, after auto-HCT, where engraftment was defined as the first of 3 consecutive measurements of platelet count ≥20 × 10\^9/L without platelet transfusion support for 7 days following the conditioning regimen associated nadir., End of engraftment period, which was defined as 29 days post transplantation|Subjects With Graft Durability at 100 Days Post Transplant/ Early Termination, Subjects achieving graft durability were defined as meeting the following 2 criteria:

* Platelet count ≥50 × 10\^9/L without transfusion for at least 2 weeks.
* Hemoglobin level ≥10 g/dL with no erythropoietin support or transfusions for at least 1 month.

This analysis was performed in part 2 of the study only., Day 100 Post-Transplantation (± 7 days)|Graft Durability at 6 Months Post Transplantation, Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 6 months post transplantation, 6 Months Post Transplantation|Graft Durability at 9 Months Post Transplantation, Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 9 months post transplantation, 9 Months Post Transplantation|Graft Durability at 12 Months Post Transplantation, Comparability of the graft durability between the BL-8040 + G-CSF arm and the placebo + G-CSF arm at 12 months post transplantation, 12 Month Post Transplantation","Overall Survival Until September 2028, Comparability between the effect of BL-8040 + G-CSF and placebo + G-CSF on Overall Survival until September 2028, End of Study|Relapse Free Survival Until September 2028, Comparability between the effect of BL-8040 + G-CSF and placebo + G-CSF on Relapse Free Survival until September 2028, End Of Study|Annualized Relapse Rate Until September 2028, Comparability between the effect of BL-8040 + G-CSF and placebo + G-CSF on Annualized Relapse Rate until September 2028, End of Study","BioLineRx, Ltd.",,ALL,"ADULT, OLDER_ADULT",PHASE3,180,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: TREATMENT",BL-8040.SCM.301,2018-03-23,2020-12-22,2029-09-30,2017-08-11,2023-11-07,2024-08-27,"UCLA Medical Center, Los Angeles, California, 167817, United States|University of Florida, Gainesville, Florida, 100278, United States|University of Miami, Miami, Florida, 33136, United States|Loyola University Medical Center, Chicago, Illinois, 60611, United States|University of Maryland, Baltimore, Maryland, 21201, United States|Mayo Clinic, Rochester, Minnesota, 55902, United States|The Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|University of Cincinnati, Cincinnati, Ohio, 45221, United States|MD Anderson Cancer Center, Houston, Texas, 77030, United States|Huntsman Cancer Institute in University of Utah, Salt Lake City, Utah, 84112, United States|University of Koln, Köln, Koln, 50923, Germany|Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases, Budapest, 1097, Hungary|University of Debrecen, Debrecen, 4032, Hungary|Div. Clinicizzata di Ematologia - Policlinico Vittorio Emanuele, Catania, 95124, Italy|Presidio Ospedaliero Morelli Viale Europa, Reggio Calabria, 89133, Italy|Hospital de La Santa Creu I Sant Pau, Barcelona, 08041, Spain|Hospital University Ramon y Cajal, Madrid, 135250, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/29/NCT03246529/Prot_SAP_000.pdf"
